Decipher Labs Limited , a pharmaceutical company, has reported financial results for the quarter ended September 30, 2025, and announced a key executive appointment.

Financial Performance

The company reported a standalone loss before tax of Rs. 5.64 lakhs for the quarter ended September 30, 2025. On a consolidated basis, the loss before tax for the half-year period stood at Rs. 340.34 lakhs.

Key Financial Highlights (Consolidated)

Segment Performance

The company operates in two segments:

1. Manufacturing and Trading of Pharmaceutical drugs
2. Consultancy Services

For the half-year ended September 30, 2025, the Consultancy Services segment contributed significantly to the revenue, generating Rs. 656.24 lakhs, while the Manufacturing and Trading of Pharmaceutical drugs segment reported revenue of Rs. 67.50 lakhs.

Executive Appointment

Decipher Labs has appointed Mr. Dalavath Amar Singh as an Additional Director in the Executive category. The appointment is for a period of two years, subject to shareholder approval, with an annual remuneration of Rs. 6 lakhs.

Mr. Amar Singh brings operational experience in the pharmaceutical industry to the board. His expertise includes plant operations, team coordination, and production processes, which are expected to provide on-ground insights to the company's strategic decisions.

Balance Sheet Position

As of September 30, 2025, Decipher Labs reported:

• Total Assets: Rs. 2,376.02 lakhs
• Total Equity and Liabilities: Rs. 2,376.02 lakhs
• Equity Share Capital: Rs. 1,010.00 lakhs

Cash Flow

The company reported a net decrease in cash and cash equivalents of Rs. 200.76 lakhs for the half-year ended September 30, 2025, with the closing balance of cash and cash equivalents standing at Rs. 80.07 lakhs.

Decipher Labs continues to operate in the pharmaceutical and consultancy sectors. The appointment of Mr. Amar Singh may signal the company's focus on strengthening its operational capabilities.

Decipher Labs Ltd, a Hyderabad-based pharmaceutical company, has received partial relief from the Securities Appellate Tribunal (SAT) against a previous Securities and Exchange Board of India (SEBI) order. The SAT's decision provides some respite for the company and its directors in the face of regulatory action.

Key Points of the SAT Order

Stay on Trading Restrictions

The SAT has granted a stay on the restrictions that prevented Decipher Labs from dealing in securities for one year, as imposed by the SEBI order dated July 31, 2025.

Directors Allowed to Sell Shares

Mr. Janakiram Ajjarapu and Mr. Sushant Mohan Lal, directors of the company, have been permitted to sell shares from their demat accounts.

Suspension of Coercive Action

The tribunal has suspended coercive action for the recovery of disgorgement and penalty amounts from the directors, subject to a condition.

Conditional Relief

The directors are required to deposit 50% of the penalty amount within four weeks from the date of the SAT order (September 16, 2025).

Background of the SEBI Order

The original SEBI order, which led to this appeal, involved alleged violations related to:

• Prohibition of Fraudulent and Unfair Trade Practices (PFUTP) Regulations
• Prohibition of Insider Trading (PIT) Regulations
• Listing Obligations and Disclosure Requirements (LODR) Regulations

Company's Statement

Decipher Labs has stated that the SAT order will have no impact on its financial, operational, or other activities. The company made this disclosure in compliance with Regulation 30 of the SEBI Listing Regulations, 2015.

Implications for Investors

While the partial relief from SAT allows Decipher Labs to continue its securities-related activities, investors should note that the case is still ongoing. The conditional nature of the relief, requiring a significant deposit from the directors, suggests that regulatory scrutiny remains.

As the situation continues to evolve, stakeholders are advised to monitor further developments and official communications from the company and regulatory bodies.